Literature DB >> 31300746

Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL.

Deyan Yordanov Yosifov1,2, Irina Idler1,2, Nupur Bhattacharya1,3, Michaela Reichenzeller1,2, Viola Close1,2, Daria Ezerina4, Annika Scheffold1, Billy Michael Chelliah Jebaraj1, Sabrina Kugler1,2, Johannes Bloehdorn1, Jasmin Bahlo5, Sandra Robrecht5, Barbara Eichhorst5, Kirsten Fischer5, Anja Weigel1, Hauke Busch6,7, Peter Lichter8, Hartmut Döhner1, Tobias P Dick4, Stephan Stilgenbauer1, Daniel Mertens9,10.   

Abstract

Chronic lymphocytic leukemia (CLL) cells depend on microenvironmental non-malignant cells for survival. We compared the transcriptomes of primary CLL cells cocultured or not with protective bone marrow stromal cells (BMSCs) and found that oxidative phosphorylation, mitochondrial function, and hypoxic signaling undergo most significant dysregulation in non-protected CLL cells, with the changes peaking at 6-8 h, directly before induction of apoptosis. A subset of CLL patients displayed a gene expression signature resembling that of cocultured CLL cells and had significantly worse progression-free and overall survival. To identify drugs blocking BMSC-mediated support, we compared the relevant transcriptomic changes to the Connectivity Map database. Correlation was found with the transcriptomic signatures of the cardiac glycoside ouabain and of the ipecac alkaloids emetine and cephaeline. These compounds were highly active against protected primary CLL cells (relative IC50's 287, 190, and 35 nM, respectively) and acted by repressing HIF-1α and disturbing intracellular redox homeostasis. We tested emetine in a murine model of CLL and observed decreased CLL cells in peripheral blood, spleen, and bone marrow, recovery of hematological parameters and doubling of median survival (31.5 vs. 15 days, P = 0.0001). Pathways regulating redox homeostasis are thus therapeutically targetable mediators of microenvironmental support in CLL cells.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31300746     DOI: 10.1038/s41375-019-0513-x

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  46 in total

Review 1.  Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.

Authors:  Philip A Thompson; William G Wierda
Journal:  Blood       Date:  2015-11-17       Impact factor: 22.113

2.  Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia.

Authors:  Andrea Bürkle; Matthias Niedermeier; Annette Schmitt-Gräff; William G Wierda; Michael J Keating; Jan A Burger
Journal:  Blood       Date:  2007-07-25       Impact factor: 22.113

Review 3.  The CLL cell microenvironment.

Authors:  Jan A Burger
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

4.  B-cell receptor signaling in chronic lymphocytic leukemia.

Authors:  Freda K Stevenson; Sergey Krysov; Andrew J Davies; Andrew J Steele; Graham Packham
Journal:  Blood       Date:  2011-08-03       Impact factor: 22.113

5.  Nurse-like cells show deregulated expression of genes involved in immunocompetence.

Authors:  Nupur Bhattacharya; Susanne Diener; Irina S Idler; Judith Rauen; Sarah Häbe; Hauke Busch; Annett Habermann; Thorsten Zenz; Hartmut Döhner; Stephan Stilgenbauer; Daniel Mertens
Journal:  Br J Haematol       Date:  2011-05-25       Impact factor: 6.998

6.  Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22.

Authors:  Paolo Ghia; Giuliana Strola; Luisa Granziero; Massimo Geuna; Giuseppe Guida; Federica Sallusto; Nancy Ruffing; Licia Montagna; Paola Piccoli; Marco Chilosi; Federico Caligaris-Cappio
Journal:  Eur J Immunol       Date:  2002-05       Impact factor: 5.532

Review 7.  Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.

Authors:  Elisa Ten Hacken; Jan A Burger
Journal:  Biochim Biophys Acta       Date:  2015-07-17

8.  Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Authors:  John C Byrd; Jennifer R Brown; Susan O'Brien; Jacqueline C Barrientos; Neil E Kay; Nishitha M Reddy; Steven Coutre; Constantine S Tam; Stephen P Mulligan; Ulrich Jaeger; Steve Devereux; Paul M Barr; Richard R Furman; Thomas J Kipps; Florence Cymbalista; Christopher Pocock; Patrick Thornton; Federico Caligaris-Cappio; Tadeusz Robak; Julio Delgado; Stephen J Schuster; Marco Montillo; Anna Schuh; Sven de Vos; Devinder Gill; Adrian Bloor; Claire Dearden; Carol Moreno; Jeffrey J Jones; Alvina D Chu; Maria Fardis; Jesse McGreivy; Fong Clow; Danelle F James; Peter Hillmen
Journal:  N Engl J Med       Date:  2014-05-31       Impact factor: 91.245

9.  CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment.

Authors:  Piers E M Patten; Andrea G S Buggins; Julie Richards; Andrew Wotherspoon; Jon Salisbury; Ghulam J Mufti; Terry J Hamblin; Stephen Devereux
Journal:  Blood       Date:  2008-03-07       Impact factor: 22.113

Review 10.  Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia.

Authors:  C Shustik; I Bence-Bruckler; R Delage; C J Owen; C L Toze; S Coutre
Journal:  Ann Hematol       Date:  2017-04-07       Impact factor: 3.673

View more
  13 in total

1.  HIF-1α: a potential treatment target in chronic lymphocytic leukemia.

Authors:  Martina Seiffert
Journal:  Haematologica       Date:  2020-04       Impact factor: 9.941

2.  Drug screening and genome editing in human pancreatic cancer organoids identifies drug-gene interactions and candidates for off-label treatment.

Authors:  Christian K Hirt; Tijmen H Booij; Linda Grob; Patrik Simmler; Nora C Toussaint; David Keller; Doreen Taube; Vanessa Ludwig; Alexander Goryachkin; Chantal Pauli; Daniela Lenggenhager; Daniel J Stekhoven; Christian U Stirnimann; Katharina Endhardt; Femke Ringnalda; Lukas Villiger; Alexander Siebenhüner; Sofia Karkampouna; Marta De Menna; Janette Beshay; Hagen Klett; Marianna Kruithof-de Julio; Julia Schüler; Gerald Schwank
Journal:  Cell Genom       Date:  2022-02

3.  Cephaeline is an inductor of histone H3 acetylation and inhibitor of mucoepidermoid carcinoma cancer stem cells.

Authors:  Luan César Silva; Gabriell Bonifácio Borgato; Vivian Petersen Wagner; Manoela Domingues Martins; Guilherme Zweig Rocha; Márcio Ajudarte Lopes; Alan Roger Santos-Silva; Gilberto de Castro Júnior; Luiz Paulo Kowalski; Jacques E Nor; Cristiane H Squarize; Rogerio Moraes Castilho; Pablo Agustin Vargas
Journal:  J Oral Pathol Med       Date:  2021-10-27       Impact factor: 3.539

Review 4.  Oxidation Impacts the Intracellular Signaling Machinery in Hematological Disorders.

Authors:  Elena Tibaldi; Enrica Federti; Alessandro Matte; Iana Iatcenko; Anand B Wilson; Veronica Riccardi; Mario Angelo Pagano; Lucia De Franceschi
Journal:  Antioxidants (Basel)       Date:  2020-04-24

5.  Exploring the significance of PAK1 through chromosome conformation signatures in ibrutinib-resistant chronic lymphocytic leukaemia.

Authors:  Zijuan Wu; Luqiao Wang; Lei Fan; Hanning Tang; Xiaoling Zuo; Danling Gu; Xueying Lu; Yue Li; Jiazhu Wu; Shuchao Qin; Yi Xia; Huayuan Zhu; Li Wang; Wei Xu; Jianyong Li; Hui Jin
Journal:  Mol Oncol       Date:  2022-07-22       Impact factor: 7.449

Review 6.  cROSsing the Line: Between Beneficial and Harmful Effects of Reactive Oxygen Species in B-Cell Malignancies.

Authors:  Krzysztof Domka; Agnieszka Goral; Malgorzata Firczuk
Journal:  Front Immunol       Date:  2020-07-21       Impact factor: 7.561

7.  Pathways, Processes, and Candidate Drugs Associated with a Hoxa Cluster-Dependency Model of Leukemia.

Authors:  Laura M Kettyle; Charles-Étienne Lebert-Ghali; Ivan V Grishagin; Glenda J Dickson; Paul G O'Reilly; David A Simpson; Janet J Bijl; Ken I Mills; Guy Sauvageau; Alexander Thompson
Journal:  Cancers (Basel)       Date:  2019-12-17       Impact factor: 6.639

8.  Ascorbic acid (vitamin C) synergistically enhances the therapeutic effect of targeted therapy in chronic lymphocytic leukemia.

Authors:  Walaa Darwiche; Cathy Gomila; Hakim Ouled-Haddou; Marie Naudot; Cécile Doualle; Pierre Morel; Florence Nguyen-Khac; Loïc Garçon; Jean-Pierre Marolleau; Hussein Ghamlouch
Journal:  J Exp Clin Cancer Res       Date:  2020-10-28

9.  Berberine affects mitochondrial activity and cell growth of leukemic cells from chronic lymphocytic leukemia patients.

Authors:  Silvia Ravera; Fabio Ghiotto; Claudya Tenca; Elena Gugiatti; Sara Santamaria; Bernardetta Ledda; Adalberto Ibatici; Giovanna Cutrona; Andrea N Mazzarello; Davide Bagnara; Martina Cardillo; Daniela Zarcone; Zbigniew Darzynkiewicz; Ermanno Ciccone; Franco Fais; Silvia Bruno
Journal:  Sci Rep       Date:  2020-10-05       Impact factor: 4.379

Review 10.  Bone Marrow Lymphoid Niche Adaptation to Mature B Cell Neoplasms.

Authors:  Erwan Dumontet; Stéphane J C Mancini; Karin Tarte
Journal:  Front Immunol       Date:  2021-12-08       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.